11:20 AM EST - BioVaxys Technology Corp : Announces that results from a collaborative research project conducted in the Bavarian Forest National Park in Germany have recently been published in the European Journal of Wildlife Research. BioVaxys Licensee SpayVac-for-Wildlife, Inc., reports further positive single-dose efficacy data for its immunocontraceptive vaccine and initiation of regulatory submission process. BioVaxys Technology Corp.
shares C.BIOV are trading unchanged at $0.27.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACNX&qmodStoryID=6368738771546208
